Celgene Co. (NASDAQ:CELG) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 14,380,412 shares, a growth of 10.3% from the January 12th total of 13,038,301 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average trading volume of 9,042,197 shares, the short-interest ratio is presently 1.6 days.

In related news, insider Mark J. Alles bought 3,260 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were acquired at an average cost of $91.90 per share, for a total transaction of $299,594.00. Following the purchase, the insider now directly owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 0.95% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Arcadia Investment Management Corp MI grew its position in Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the period. Thompson Davis & CO. Inc. grew its position in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the period. Robecosam AG acquired a new stake in Celgene during the third quarter valued at $114,000. Capital Bank & Trust Co grew its position in Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 517 shares during the period. Finally, Guidant Wealth Advisors acquired a new stake in Celgene during the third quarter valued at $119,000. Institutional investors own 78.93% of the company’s stock.

Celgene (NASDAQ CELG) opened at $92.51 on Monday. The company has a current ratio of 4.99, a quick ratio of 3.52 and a debt-to-equity ratio of 2.29. Celgene has a fifty-two week low of $88.32 and a fifty-two week high of $147.17. The stock has a market cap of $69,580.00, a price-to-earnings ratio of 25.63, a P/E/G ratio of 0.66 and a beta of 1.49.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The firm had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. During the same quarter last year, the company posted $1.61 earnings per share. The firm’s revenue was up 16.9% compared to the same quarter last year. analysts forecast that Celgene will post 7.68 EPS for the current year.

A number of equities analysts have recently issued reports on CELG shares. Cantor Fitzgerald set a $162.00 price objective on shares of Celgene and gave the company a “buy” rating in a research note on Monday, October 16th. Jefferies Group reiterated a “buy” rating and set a $160.00 price objective on shares of Celgene in a research note on Monday, October 16th. BMO Capital Markets increased their price objective on shares of Celgene from $160.00 to $167.00 and gave the company a “positive” rating in a research note on Tuesday, October 17th. Sanford C. Bernstein started coverage on shares of Celgene in a research note on Tuesday, October 17th. They set an “outperform” rating and a $162.00 price objective on the stock. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a research note on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $130.35.

TRADEMARK VIOLATION NOTICE: “Celgene Co. (CELG) Short Interest Update” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://theolympiareport.com/2018/02/12/celgene-co-celg-short-interest-update.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.